Overview

Androgen Deprivation, With or Without pTVG-AR, and With or Without Nivolumab, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Status:
Not yet recruiting

Trial end date:
2025-04-01

Target enrollment:

Participant gender:

Summary

The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with nivolumab, to induce and/or augment therapeutic T-cells following androgen deprivation in patients with newly diagnosed prostate cancer scheduled to undergo prostatectomy. Patients without evidence of metastatic disease, with tissue remaining from a pre-treatment biopsy, and who are being considered for standard treatment by prostatectomy, will be invited to participate and will be on study for up to 15 months.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborators:

Madison Vaccines, Inc
United States Department of Defense

Treatments:

Nivolumab